Tuesday, February 28, 2017

STD Diagnostics Market Analysis, Size, Share, Growth and Forecast to 2024 | Hexa Research

The global STD (sexually transmitted disease) Diagnostics Market is driven by growing awareness about STDs among the masses and greater governmental initiatives. Technological developments too play a vital role in fuelling market growth. Popularity of POC (point of care) testing propels the demand for improved products, such as diagnostic devices, kits, and reagents. A number of people have multiple sexual partners which in turn raises the possibility of contracting infections. Hence, there’s the growing need for accurate & precise diagnostics solutions.
The worldwide STD diagnostics market is segmented as per types of infections, location of tests, devices, and regions. On the basis of infections, the categories are human papilloma virus (HPV), syphilis, chlamydia, vaginitis, HIV (human immunodeficiency virus), herpes simplex virus, and gonorrhea. Chlamydia, gonorrhea, and syphilis are sexually transmitted infections (STIs) caused by bacteria.

Genital warts, HPV, HIV, and hepatitis genital herpes are examples of STIs caused by viruses. These microorganisms get transmitted through semen, blood, and vaginal fluids. Chlamydia is by far the most commonly occurring sexually transmitted disease.


In terms of revenues, this segment held the highest share in the overall industry. It generated revenues surpassing USD 36 billion in 2016.  However, rising cases of syphilis may contribute to more than 20% of total industry revenues over the forecast period (2016 to 2024).

Based on location of tests, the market is bifurcated into laboratory testing and point of care (PoC) testing.
Laboratory tests are carried out either in public health labs or in private/commercial labs. Unlike, PoC testing solutions, laboratory tests deliver more precise results. PoC tests (such as test kits) are a more convenient option because these deliver immediate results, but they are not always accurate. The introduction of bedside & mobile testing is a step towards enhanced healthcare. The industry for bedside & mobile testing may expand at a CAGR nearly 10% from 2016 to 2024.

According to type of device, the worldwide STD diagnostics market is segmented into thermal cyclers - PCRs, lateral flow readers, flow cytometers, differential light scattering machines, absorbance microplate reader, phone chips (microfluidics+ICT), and bench top/portable/rapid diagnostics kits. Portable/rapid diagnostics and phone chips are PoC testing devices, while the others are laboratory test devices. The thermal cyclers segment is anticipated to grow rapidly at a CAGR surpassing 8% during the forecast period. The portable PoC testing devices industry is propelled by continuous technological innovations. It may generate revenues exceeding USD 46 billion by 2024.

Geographically, the global STD diagnostics market is divided into Asia Pacific, North America, Latin America, Europe, and the Middle East & Africa. Driven by surging public awareness about STIs and the presence of a well developed system of health insurance, North America dominates the global industry. Another vital factor that positively impacts this region is the growing accessibility to FDA-approved highly advanced testing devices. As per ongoing industry trends, Asia Pacific may register a high CAGR over the forecast period and thus prove to be a lucrative market in the long run. Prominent companies operating in the worldwide STD diagnostics market are Danaher Corporation, Abbott Laboratories, BioMerieux, Roche Holdings AG, and Becton Dickinson & Company.

Recently, QuantuMDx, a U.K. based company dealing in life sciences diagnostics & tools, developed the Q-Poc. This is a highly affordable diagnostic DNA analyzer which is commonly known as the “handheld lab”. It is capable of diagnosing certain types of cancers and a number of infectious diseases (including the sexually transmitted ones). Equipped with a solar battery, the Q-Poc can analyze biological samples, for example, swabs are used to detect sexually transmitted diseases/infections.

Browse Related Category Market Reports @


About Us:
Hexa Research is a market research and consulting organization, offering industry reports, custom research and consulting services to a host of key industries across the globe. We offer comprehensive business intelligence in the form of industry reports which help our clients obtain clarity about their business environment and enable them to undertake strategic growth initiatives.

Contact Us:
Ryan Shaw
Hexa Research
Felton Office Plaza
6265 Highway 9
Felton, California 95018
United States
Phone: +1-800-489-3075
Visit Our Blog - hexaresearch1.blogspot.com

Monday, February 13, 2017

Autoimmune Disease Diagnostics Market Size, Share, Growth and Forecast to 2020 | Hexa Research

Factors that propel the Global Autoimmune Disease Diagnostics Market are rising cases of autoimmune diseases and surging healthcare expenditure. Encouraging governmental policies regarding autoimmune diagnostics & research has a positive impact on market demand. Autoimmune diseases are a key cause of women deaths worldwide. Furthermore, active awareness initiatives regarding diagnosis of diseases may contribute significantly to the global industry during the forecast period (2012 to 2020). A large number of laboratories have begun installing equipment that can carry out several tests simultaneously and deliver quick results. Automation in laboratory procedures ensures greater efficiency.

The worldwide autoimmune disease diagnostics market is categorized on the basis of products and regions. On the basis of products, there are two key segments, namely, localized disease diagnostics and systemic autoimmune disease diagnostics. Owing to greater patient awareness and huge procedure volumes, the localized disease diagnostics segment held the highest share in 2013.

Browse Details of Report@

A number of unmet medical needs in type 1 diabetics is a key factor that drives this segment. The systemic autoimmune disease diagnostics segment mainly involves the diagnosis of diseases, such as rheumatoid arthritis, lupus erythematosus (SLE), and Ankylosing spondylitis. The rheumatoid arthritis segment holds the highest share in the industry because it is the most frequently occurring inflammatory ailment worldwide. It is led by product innovation.

On the basis of geographies, the global autoimmune disease diagnostics market is divided into Europe, Asia Pacific, North America, and Rest of the World. In revenue terms, North America was the largest market in 2013. This region is propelled by a well developed healthcare infrastructure and positive government initiatives, such as the Affordable Care Act and Patient Protection Act.

In terms of yearly expenditure on autoimmune disease diagnostics, North America ranks number one in the overall industry. Moreover, surging per capita spending on healthcare is projected to significantly drive regional growth till 2020. Europe, the second largest market after North America, is propelled by technological advancements and high cases of autoimmune diseases. These technological developments are mainly observed in portable diagnostics equipment and biomarkers. Europe may derive much of its demand for autoimmune disease diagnostics from Eastern Europe.

Being a highly consolidated one, the global market for autoimmune disease diagnostics market witnesses frequent mergers & acquisitions. It is a moderately competitive industry that is led by innovations and price wars. Key competitors in the global industry are Bio Rad, Crescendo Bioscience, Roche Diagnostics, Quest Diagnostics, and Abbott Diagnostics.

In October 2016, IQuity, a diagnostics technology company launched the IQIsolate® technology. This technology helps identify autoimmune anomalies during its early stages. It analyzes the RNA structures in blood samples. Interestingly, IQIsolate® has exhibited ninety percent accuracy in three key medical specialties, namely, rheumatology, gastroenterology, and neurology. The company asserts that its technology can significantly reduce the diagnostics processes of complex autoimmune diseases. It can also differentiate between diseases that show similar symptoms. A striking feature of IQuity’s blood based diagnostic technology is that it helps providers & physicians confirm other types of autoimmune anomalies within a week. It is expected to gradually commercialize newer test panels that focus on rheumatology and gastroenterology.

Browse Related Category Market Reports @


About Us:
Hexa Research is a market research and consulting organization, offering industry reports, custom research and consulting services to a host of key industries across the globe. We offer comprehensive business intelligence in the form of industry reports which help our clients obtain clarity about their business environment and enable them to undertake strategic growth initiatives.

Contact Us:
Ryan Shaw
Hexa Research
Felton Office Plaza
6265 Highway 9
Felton, California 95018
United States
Phone: +1-800-489-3075
Visit Our Blog - hexaresearch1.blogspot.com